WHO ICTRP trial
A Randomized, Double-Blind, Placebo-Controlled, Crossover, Phase IIa Study to…
EUCTR2005-006118-17-DE · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2005-006118-17-DE |
|---|---|
| Public title | A Randomized, Double-Blind, Placebo-Controlled, Crossover, Phase IIa Study to Evaluate Efficacy and Safety of the beta3-Adrenergic Receptor Agonist Solabegron in Subjects with Irritable Bowel Syndrome - N/A |
| Scientific title | A Randomized, Double-Blind, Placebo-Controlled, Crossover, Phase IIa Study to Evaluate Efficacy and Safety of the beta3-Adrenergic Receptor Agonist Solabegron in Subjects with Irritable Bowel Syndrome - N/A |
| Primary sponsor | GlaxoSmithKline Research and Development Limited |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Germany |
| Conditions | Irritable Bowel Syndrome (IBS) |
| Interventions | Product Name: Solabegron Product Code: GW427353 Pharmaceutical Form: Tablet INN or Proposed INN: Solabegron CAS Number: 451470-34-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form… |
| Registration date | Jun 14, 2006 |
| Target size | 100 |
| Secondary IDs | B3I105940 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: